|
Phase I-II open label multicenter study of PD0332991 in BRAFV600mut metastatic melanoma patients harboring CDKN2A loss and RB1 expression and treated with vemurafenib. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Incyte; MSD; Novartis; Roche |
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Roche |
Research Funding - Roche (Inst) |
Travel, Accommodations, Expenses - MSD; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Pierre Fabre |
Consulting or Advisory Role - Bristol-Myers Squibb; Pierre Fabre |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Innate Pharma; Leo Pharma; Takeda |
Consulting or Advisory Role - Innate Pharma |
|
|
Consulting or Advisory Role - Novartis; Roche |
Research Funding - Biocartis (Inst) |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer; Pierre Fabre; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Novartis; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
Other Relationship - Avantis Medical Systems |